BACKGROUND: ras genes encode Ras proteins that are important for signal transduction in cancer cells. Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras. PATIENTS AND METHODS: We report the results of a phase II trial of SCH 66336, an FPTase inhibitor, in patients with metastatic colorectal cancer. This is the first reported experience of an FPTase inhibitor in this disease. All patients were considered refractory to first- and second-line therapy. A total of 21 evaluable patients were treated with a starting dose of 200 mg b.i.d. given continuously. RESULTS: The major side-effects were fatigue (grade 1 in 42%, grade 2 in 42% and grade 3 in 14%), diarrhea (grade 1 in 23% and grade 3 in 42%) and nausea (grade 2 in 16%). Elevations in serum creatinine (grade 2 or 3) were observed in 19% of patients and appeared to be related to dehydration induced by diarrhea. Significant hematological toxicity was not observed (only grade 1 thrombocytopenia in 19% and grade 2 or 3 anemia in 28%). Pharmacological studies revealed adequate mean pre-dose plasma concentrations in this group of patients on day 15 of therapy. No objective responses were observed, although stable disease was seen in three patients for several months. Administration of SCH 66336 was accompanied by gastrointestinal toxicity. CONCLUSIONS: Future development of this compound cannot be recommended as monotherapy in this disease.
BACKGROUND: ras genes encode Ras proteins that are important for signal transduction in cancer cells. Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras. PATIENTS AND METHODS: We report the results of a phase II trial of SCH 66336, an FPTase inhibitor, in patients with metastatic colorectal cancer. This is the first reported experience of an FPTase inhibitor in this disease. All patients were considered refractory to first- and second-line therapy. A total of 21 evaluable patients were treated with a starting dose of 200 mg b.i.d. given continuously. RESULTS: The major side-effects were fatigue (grade 1 in 42%, grade 2 in 42% and grade 3 in 14%), diarrhea (grade 1 in 23% and grade 3 in 42%) and nausea (grade 2 in 16%). Elevations in serum creatinine (grade 2 or 3) were observed in 19% of patients and appeared to be related to dehydration induced by diarrhea. Significant hematological toxicity was not observed (only grade 1 thrombocytopenia in 19% and grade 2 or 3 anemia in 28%). Pharmacological studies revealed adequate mean pre-dose plasma concentrations in this group of patients on day 15 of therapy. No objective responses were observed, although stable disease was seen in three patients for several months. Administration of SCH 66336 was accompanied by gastrointestinal toxicity. CONCLUSIONS: Future development of this compound cannot be recommended as monotherapy in this disease.
Authors: Nan Soon Wong; Kellen L Meadows; Lee S Rosen; Alex A Adjei; Scott H Kaufmann; Michael A Morse; William P Petros; Yali Zhu; Paul Statkevich; David L Cutler; Michael L Meyers; Herbert I Hurwitz Journal: Cancer Invest Date: 2011-11 Impact factor: 2.176
Authors: Husheng Ding; Jennifer Hackbarth; Paula A Schneider; Kevin L Peterson; X Wei Meng; Haiming Dai; Thomas E Witzig; Scott H Kaufmann Journal: Blood Date: 2011-06-14 Impact factor: 22.113
Authors: Kimmie Ng; Shuji Ogino; Jeffrey A Meyerhardt; Jennifer A Chan; Andrew T Chan; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Monica M Bertagnolli; Alan P Venook; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2011-08-17 Impact factor: 13.506
Authors: Bruno B Bordier; Junko Ohkanda; Ping Liu; So-Young Lee; F H Salazar; Patricia L Marion; Kazuo Ohashi; Leonard Meuse; Mark A Kay; John L Casey; Said M Sebti; Andrew D Hamilton; Jeffrey S Glenn Journal: J Clin Invest Date: 2003-08 Impact factor: 14.808